Herpes Zoster

Detailed Overview

Following a primary infection with VZV (chickenpox), the virus travels retrogradely along sensory nerves to the dorsal root ganglia where it lies dormant for decades. As cellular immunity to VZV wanes with advancing age, immunosuppression, or severe stress, the virus reactivates. It replicates in the ganglion and travels anterogradely down the sensory nerve to the skin, causing severe neuropathic pain and a unilateral vesicular eruption strictly limited to a single dermatome. The most feared complication is postherpetic neuralgia (PHN), which can cause debilitating, treatment-resistant nerve pain persisting for months to years after the rash resolves. Prompt antiviral therapy is critical to reduce the duration of the rash and the severity of PHN.

Epidemiology & Demographics

Incidence: ~4 cases per 1,000 person-years in the general population, rising to >10 per 1,000 in those over 60. Lifetime risk: 1 in 3 adults will develop shingles. Age distribution: Drastic increase in incidence after age 50.

Etiological Mechanism

Reactivation of endogenous Varicella-Zoster Virus (Human Herpesvirus 3).

Primary Causes

Primary: Reactivation of latent VZV

Secondary (Triggers): Age-related immunosenescence, immunosuppressive drugs, HIV/AIDS, malignancy, extreme psychological stress

• Advanced Age: The most significant risk factor; incidence spikes dramatically after 50 years of age due to declining T-cell immunity.
• Immunocompromised State: Patients on chemotherapy, chronic high-dose corticosteroids, or with HIV have higher incidence and risk of disseminated disease.
• Physical Trauma: Trauma to a specific sensory nerve or spinal root can trigger reactivation in that dermatome.

During childhood chickenpox, VZV infects the mucocutaneous tissues, then enters sensory nerve endings, traveling via retrograde axonal transport to the dorsal root, cranial nerve, or autonomic ganglia. Here, VZV establishes latency. The virus produces latency-associated transcripts but no infectious virions. The latency is maintained by VZV-specific memory T-cells. When this cell-mediated immunity drops below a critical threshold (due to age or immunosuppression), the virus begins replicating within the ganglion. This causes intense neuronal inflammation and necrosis, translating to severe pre-eruptive neuropathic pain. The newly formed virions then travel anterogradely down the sensory axon to the epidermal cells of the corresponding dermatome. Viral replication in the epidermis causes ballooning degeneration of keratinocytes, fluid accumulation, and the formation of characteristic grouped vesicles on an erythematous base.

Characteristic Clinical Presentation

• Prodromal Pain: Burning, tingling, or stabbing neuropathic pain in a specific area 2-3 days before the rash appears.
• Unilateral Rash: Erythematous maculopapular rash that quickly evolves into grouped, fluid-filled vesicles.
• Hyperesthesia/Allodynia: Extreme sensitivity to touch; even clothing brushing against the skin causes severe pain.
• Constitutional Symptoms: Low-grade fever, headache, and malaise may accompany the rash.

Physical Examination Signs

• Grouped vesicles on an erythematous base
• Strict dermatomal distribution, unequivocally not crossing the body's midline
• Thoracic and lumbar dermatomes are most commonly involved
• Hutchinson's sign: vesicles on the tip of the nose, indicating V1 branch of trigeminal nerve involvement and high risk for ocular shingles

• Postherpetic Neuralgia (PHN): Chronic, debilitating nerve pain occurring in 10-15% of patients, characterized by severe allodynia.
• Herpes Zoster Ophthalmicus: Involvement of the ophthalmic branch of CN V; can cause keratitis, uveitis, and permanent blindness.
• Herpes Zoster Oticus (Ramsay Hunt Syndrome): Involvement of the geniculate ganglion causing facial paralysis, ear pain, and vesicles in the ear canal/tympanic membrane.
• Bacterial Superinfection: Secondary infection of the vesicles, usually by S. aureus or S. pyogenes.

Diagnostic Criteria & Guidelines

Diagnosis is almost always clinical based on the characteristic unilateral dermatomal rash with associated neuropathic pain. If the presentation is atypical (e.g., in immunocompromised patients), diagnosis is confirmed via PCR testing of vesicle fluid.

Differential Diagnosis

• Herpes Simplex Virus (can cause zosteriform localized rash)
• Contact Dermatitis (e.g., Poison Ivy - usually crosses midline and itches rather than burns)
• Erysipelas / Cellulitis
• During prodrome: Myocardial Infarction, Cholecystitis, or Herniated Disc

Laboratory Tests & Biomarkers

• VZV Polymerase Chain Reaction (PCR): Positive from unroofed vesicle fluid swab (Test of choice for confirmation).
• Tzanck Smear: Shows multinucleated giant cells (cannot distinguish between VZV and HSV; largely historically significant).

Imaging Modalities & Findings

• None typically required:

• Prodrome
  Neuropathic pain without visible skin changes (can mimic MI, pleurisy, or sciatica).
• Acute Eruptive
  Vesicles appear, then turn into pustules, and crust over within 7-10 days.
• Postherpetic Neuralgia
  Pain persisting in the dermatome for >90 days after rash onset.

Second-Line & Adjunctive Therapy

For Postherpetic Neuralgia (PHN): Gabapentin 300 mg PO TID titrated up to 3600 mg/day, Pregabalin 75 mg PO BID, or Tricyclic Antidepressants (Amitriptyline 10-25 mg PO QHS). Topical lidocaine 5% patches.

Surgical & Procedural Management

None.

Recommended Lifestyle Changes

• Keep the rash clean and dry to prevent bacterial superinfection
• Cover the rash with a non-stick dressing
• Avoid contact with pregnant women, premature infants, and immunocompromised individuals who have not had chickenpox

Patient Counseling & Advice

Explain that shingles is a reactivation of their own childhood chickenpox virus. Emphasize taking the antiviral medication exactly as prescribed to prevent nerve damage. Clarify that while they cannot give someone else shingles, the fluid in the blisters contains active chickenpox virus and can give chickenpox to someone who is not immune.

Follow-Up & Monitoring Schedule

Outpatient follow-up in 2-4 weeks to assess for resolution of rash and presence of PHN. Immediate referral to ophthalmology is mandatory if Hutchinson's sign is present or if the eye is red/painful.

Preventive Strategies

Recombinant Zoster Vaccine (Shingrix): 2 doses given IM, 2-6 months apart. Highly effective (>90%) at preventing shingles and PHN. Recommended for all adults >= 50 years old, and immunocompromised adults >= 19 years old.

The rash usually heals in 2 to 4 weeks with no scarring. Prognosis is generally good, but older adults have a significantly higher risk of prolonged, quality-of-life limiting PHN.